Crawley

Researchers are evaluating a new oral medicine called SNV1521 for adults with advanced solid tumors. This Phase 1, open-label study aims to assess the safety, tolerability, and potential effectiveness of SNV1521 alone or combined with other cancer therapies. The study focuses on determining the best dose that is both safe and effective for treating these advanced cancers. Participants receive SNV1521 tablets with doses and schedules that vary depending on the treatment group. Some groups may also receive additional drugs such as DB-1310 through infusion, or oral medications like Abiraterone and Darolutamide following approved dosing guidelines. The study includes dose escalation and expansion periods to explore different dosing options. During the study, participants will be closely monitored for safety and side effects from the first dose through up to 13 months. Researchers will also track any dose-limiting toxicities in the first 28 days of treatment. Assessments include measuring tumor response based on established criteria and evaluating overall health and performance status. The study helps identify the best treatment approach for advanced solid tumor patients while carefully observing their well-being.